Related by context. All words. (Click for frequent words.) 87 double blind placebo 84 randomized placebo controlled 83 placebo controlled 80 blind randomized placebo 80 multicenter randomized double 79 randomized controlled 78 randomized 76 blind randomized 76 prospective randomized 75 multicenter 74 blind placebo controlled 74 Phase III randomized 73 placebo controlled randomized 72 randomized multicenter 72 multicenter randomized 71 multicentre randomized double 71 multicentre 70 randomized clinical 69 placebo controlled Phase 69 double blinded randomized 69 double blinded placebo 68 dose escalation trial 68 prospective randomized placebo 68 multicenter randomized placebo controlled 67 controlled multicenter 67 randomized Phase III 67 randomized controlled trial 66 prospective randomized controlled 66 dose escalation study 66 multicenter study 66 multicenter placebo controlled 65 label multicenter 65 blinded placebo controlled 65 prospective observational 65 Phase 2b study 65 Phase IIb 64 single ascending dose 64 randomized Phase 64 Phase IIIb 64 Phase 1b clinical 64 active comparator 64 placebo controlled clinical 64 phase IIb clinical 64 Phase III clinical 63 multicenter prospective 63 placebo controlled Phase III 63 Phase 2b clinical 63 pivotal Phase III 63 ascending dose 63 blind multicenter 63 TMC# C# 63 randomized controlled clinical 63 multicentre randomized 63 prospective randomized multicenter 63 Phase IIb trial 63 pivotal Phase 63 blind placebo 63 Phase 2a clinical 62 multicenter randomized controlled 62 multicenter clinical 62 masked placebo controlled 62 label dose escalation 62 multicenter Phase II 62 prospective multicenter 62 Phase 2b trial 62 Phase III placebo controlled 62 clinical trial 62 randomized #:# 62 dose escalation 62 Phase IIa 62 multicenter multinational 62 prospective cohort 62 Phase Ib 61 Phase Ib clinical 61 Randomized 61 multicenter Phase 61 tolerability 61 prospective multicenter randomized 61 safety tolerability pharmacokinetics 61 phase IIa 61 randomized blinded 61 Phase 1b trial 61 Phase III 61 Phase 2b 61 Phase 1b 61 multicenter Phase III 61 Phase 2a trial 60 phase IIb 60 Phase 2b randomized 60 randomized multicentre 60 dose dose escalation 60 randomized blinded placebo 60 phase IIa clinical 60 blinded randomized 60 safety tolerability 60 TAXUS ATLAS 60 nonrandomized 60 Phase Ia 60 multiple ascending dose 60 Sorafenib HCC Assessment 60 comparing XIENCE V 60 Phase IIa trial 60 phase 2a 60 NO# [002] 59 Phase IIb clinical 59 placebo controlled studies 59 blinded randomized placebo controlled 59 RE LY ® 59 phase Ib 59 Randomised 59 Placebo controlled 59 pharmacodynamics 59 controlled dose escalation 59 COMFORT II 59 multicenter phase 59 randomized controlled Phase 59 dose escalation Phase 59 multicentre study 58 VICTOR E1 58 placebo controlled dose escalation 58 observer blinded randomized 58 dose cohorts 58 TG MV 58 randomized crossover 58 pharmacokinetic 58 placebo controlled trials 58 non inferiority 58 ascending doses 58 Phase IIa clinical 58 Phase #/#a 58 HCV SPRINT 58 Phase 2a 58 observational study 58 pharmacokinetics PK 58 dosing cohorts 58 BRIM3 58 pharmacokinetics 58 randomized controlled trials 58 randomized clinical trials 58 Phase 1a 57 phase IIIb 57 label multicenter randomized 57 prospective nonrandomized 57 ADVANCE PD 57 randomized multicenter trial 57 ExTRACT TIMI 57 AIR CF1 57 blind randomized controlled 57 Phase Ib II 57 BRIM2 57 randomized Phase IIb 57 Phase III pivotal 57 viral kinetic 57 primary endpoint 57 LUX Lung 57 Phase III randomized placebo 57 dose regimens 56 dose escalation clinical 56 #:# randomization 56 Phase IIIb study 56 subanalysis 56 Phase III multicenter 56 EURIDIS 56 multinational multicenter randomized 56 Phase IIIb clinical 56 APTIVUS 56 dyskinesia PD LID 56 randomized controlled multicenter 56 ONTARGET 56 trials RCTs 56 APEX PD 56 mg BID 56 Randomized Evaluation 56 prospectively randomized 56 ANCHOR trial 56 randomized trials 56 EVEREST II 56 label multicenter Phase 56 prospective multicentre 56 landmark ATHENA 56 HPTN 56 REALITY Trial 56 Phase III clinical trials 55 oral deforolimus 55 AIR CF2 55 SPIRIT III 55 EDEMA3 55 RE LY 55 substudy 55 randomized Phase 2b 55 multicenter randomized clinical 55 mg QD 55 treatment naive genotype 55 pharmacokinetic PK 55 GetGoal Phase III 55 CLL8 55 desvenlafaxine succinate 55 dosing regimens 55 phase IIb trial 55 Phase III confirmatory 55 label dose titration 55 Phase III randomized controlled 55 Randomized Double Blind Placebo 55 rALLy clinical trial 55 randomized placebo 55 Initiated Phase 55 CLARITY study 55 treatment naïve genotype 55 primary efficacy endpoint 55 BR.# 55 oral rivaroxaban 55 placebo controlled clinical trials 55 PRE SURGE 55 telaprevir dosing 55 safety tolerability pharmacokinetic 54 LibiGel Phase III 54 mg dose 54 Prostate Lung Colorectal 54 FAME Study 54 PRECiSE 54 dose titration 54 #mg/day [001] 54 LEXIVA r 54 ENDEAVOR IV 54 Pivotal Trial 54 forodesine 54 Phase Ib study 54 unblinded 54 monotherapy 54 TRANSFORMS 54 Phase IIb randomized 54 investigational oral 54 dabigatran etexilate 54 Edge STudy 54 prospectively defined 54 MEND CABG 54 ROCKET AF 54 randomized controlled clinical trials 54 Randomized Double blind 54 ENESTnd 54 pharmacokinetic profile 54 pharmacokinetic PK study 54 placebo 54 vicriviroc 54 HCV RESPOND 2 54 phase IIb study 54 Multicenter 54 peginterferon alfa 2b 54 ongoing Phase 1b 54 EQUATE OB 54 ToGA 54 SCH # 54 mg administered orally 54 symptomatic BPH 54 Phase Ib clinical trials 54 Parkinson disease levodopa induced 54 ABSORB clinical 54 OLYMPIA registry 54 evaluable patients 54 Randomized Phase 54 CHAMPION PCI 54 placebo controlled multicenter 54 multicentre prospective 54 Acute Ischemic Stroke 54 pharmacokinetic studies 54 nab paclitaxel 53 Phase 1b dose escalation 53 Phase 1a clinical 53 SPIRIT FIRST 53 AIR CF3 53 secondary efficacy endpoints 53 dosing 53 secondary endpoint 53 Phase II 53 confirmatory Phase III 53 randomized #:#:# 53 administered subcutaneously 53 randomly assigned 53 blind multicentre 53 MIVI III 53 Phase III Clinical Trial 53 Tolvaptan 53 Placebo Controlled 53 MERLIN TIMI 53 demonstrated statistically significant 53 comparator arm 53 retrospective cohort study 53 randomized multicenter Phase III 53 ECASS 53 RE LY trial 53 clinical pharmacology studies 53 pivotal bioequivalence 53 diabetic neuropathic pain 53 BOLDER II 53 pharmacodynamic 53 Multicenter Randomized Double 53 tolerability profile 53 ACTEMRA TM 53 Phase #b/#a 53 evaluating tivozanib 53 dose regimen 53 Randomized controlled 53 EQUIP OB 53 Efficacy 53 Traficet EN 53 PRECISE 53 mg RDEA# 53 Betaferon ® 53 analgesic efficacy 53 blinded placebo 53 XIENCE V Stent System 53 CAMMS# 53 pegylated interferon alfa 2a 53 nitazoxanide 53 evaluating REVLIMID 53 interferon gamma 1b 53 NSABP B 53 phase Ib clinical 53 APPRAISE 53 posaconazole 53 viral kinetics 53 pharmacodynamic profile 53 RE SURGE 53 Carotid Revascularization Endarterectomy vs. 53 Denufosol 53 pegylated interferon alfa 2b 53 Phase IIb III 52 fostamatinib 52 BCIRG 52 e HEALING 52 Val HeFT 52 oral ridaforolimus 52 RECORD1 52 controlled multicenter Phase 52 OPT CHF 52 registrational 52 primary hypercholesterolemia 52 Phase IIB 52 RG# ITMN 52 Laquinimod 52 Phase 2b kidney transplant 52 Multi Ethnic Study 52 opioid induced bowel dysfunction 52 RIO Lipids 52 DAPT 52 Intervention Trial GAIT 52 ABSORB trial 52 Multiple Ascending Dose 52 Myocardial Infarction Study 52 Phase III trials 52 Taxotere ® 52 lubiprostone 52 observational studies 52 secondary endpoints 52 Phase Ib IIa 52 CATIE AD 52 APTIVUS r 52 Clinical Antipsychotic Trials 52 CERVARIX 52 LCP AtorFen 52 #mg QD [002] 52 Trial Evaluating 52 Controlled Trial 52 plus Copegus R 52 Phase IIa trials 52 pegylated interferon 52 null responder HCV 52 SUCCEED trial 52 multicentre randomized controlled 52 CUSTOM II 52 Matrix Phase 2b 52 huC# DM4 52 PreCISe 52 laquinimod 52 REVLIMID lenalidomide 52 AIR2 Trial 52 SPIRIT IV 52 AVOREN 52 Raloxifene Evaluation MORE 52 Zenvia ™ 52 meta analysis 52 Dacogen injection 52 ritonavir boosted atazanavir 52 MIST II 52 pharmacodynamics PD 52 GOUT 52 Trandolapril 52 Randomized Controlled 52 confirmatory Phase 3 52 icatibant 52 ENDEAVOR II 52 RSD# oral 52 Endovascular Valve Edge 52 CTA# Injection 52 longitudinal cohort study 52 plus ribavirin 52 n = 52 DURATION 52 CRx 52 PREZISTA r 52 CIMZIA TM certolizumab pegol 52 Randomized Clinical Trial 52 Dabigatran etexilate 52 Phase 1b clinical trials 52 noninferiority 52 Initiate Phase 52 trodusquemine 52 INCB# [001] 52 rosuvastatin 52 dose escalation phase 52 Phase IIA 52 EINSTEIN DVT 52 registrational trial 51 Phase III Pivotal 51 Metabolic Efficiency 51 ACTEMRA 51 pharmacodynamic PD 51 Communities ARIC study 51 STEALTH C 51 PROPEL trial 51 efficacy 51 ZYBRESTAT fosbretabulin 51 pramlintide 51 comparing alemtuzumab 51 DSMB 51 REVIVE Diabetes 51 Phase IIb trials 51 dose cohort 51 fluticasone furoate 51 AIM HIGH 51 ARDIS 51 teriflunomide 51 antiretroviral naive 51 Phase 2b clinical trials 51 TRITON TIMI 51 sunitinib malate 51 Oral Fingolimod 51 landmark ATHENA study 51 unblinding 51 lacosamide 51 de novo kidney transplant 51 ASCEND HF 51 PRoFESS 51 REYATAZ r 51 EORTC 51 dosing regimen 51 insulin detemir 51 INSPIRE Trial Phase III 51 International Verapamil SR 51 By JENNIFER LEARN 51 glatiramer acetate 51 NCT# ClinicalTrials.gov 51 post hoc 51 Intervention Effectiveness 51 REG2 51 ALN VSP Phase 51 ritonavir boosted 51 ADAGIO study 51 EFAPROXYN 51 zonisamide SR 51 pitavastatin 51 RoACTEMRA 51 Amrubicin 51 ALSYMPCA 51 Polyp Prevention Trial 51 bepotastine besilate nasal spray 51 HCV NS5B polymerase 51 metastatic HRPC 51 Prospective Randomized 51 II Clinical Trial 51 pharmacokinetic pharmacodynamic 51 IIa trial 51 Multicentre 51 NATRECOR ® 51 tolerability pharmacokinetics 51 ASTEROID 51 mg/m2 dose 51 CombAT 51 AZILECT R 51 recurrent malignant glioma 51 TAXUS VI 51 AEGR 51 ascending dose study 51 riociguat 51 Phase III psoriasis 51 observational cohort study 51 subcutaneously administered 51 lexidronam injection 51 confirmatory clinical 51 ORACLE MS 51 relapsing multiple sclerosis 51 Phase IIb Trial 51 evaluable 51 ELONVA 51 mcg kg 51 Study ADX# 51 HOPE TOO 51 Study Evaluating 51 everolimus eluting stent 51 Clinical Study 51 ABC/3TC 51 ACTIVE W 51 adjunctive placebo 51 NCCTG 51 multicenter dose escalation 51 Pivotal Phase 51 Controlled Study 51 patients evaluable 51 LITHE 51 phase III ACCLAIM 51 Prostate Cancer Prevention 51 JAK inhibitor 51 ENVISION 51 TAXUS IV 51 prasterone 51 docetaxel Taxotere R 51 azilsartan medoxomil 51 clinical trials 51 μg dose 51 trastuzumab emtansine T DM1 51 PRTX 51 number NCT# ClinicalTrials.gov 51 CALGB 51 primary endpoints 51 RELOVAIR ™ 51 mGluR5 negative 51 STRIDE PD 51 paclitaxel poliglumex 51 evaluating nimotuzumab 51 postmenopausal women 51 CANCIDAS 51 Randomized Phase II 51 multicenter randomized Phase 51 dose placebo controlled 51 CIMZIA TM 51 KRN# 51 retrospective observational study 51 ORAL Sync 51 PERSEUS clinical program 51 Allovectin 7 ® 50 recurrent glioblastoma multiforme 50 dosing cohort 50 CONQUER OB 50 PFO migraine 50 Phase III metastatic melanoma 50 evaluating Actimmune 50 FOSRENOL R 50 peginterferon alfa 2a 50 Blind Placebo Controlled 50 tanespimycin 50 sirolimus eluting stent 50 oral prodrug 50 TMC# [002] 50 ceftazidime 50 DU #b 50 bosentan 50 inhalations twice 50 ORENCIA ® 50 RRMS patients 50 colesevelam HCl 50 Monotherapy 50 phase IIb III 50 ABCSG 50 NOXAFIL Oral Suspension 50 hour bronchodilation 50 docetaxel 50 Cardiac Allograft Rejection 50 rotigotine 50 evaluating Vectibix 50 NCT# 50 BENICAR HCT 50 fosbretabulin 50 ORMD 50 bile duct tumor 50 tolerated dose MTD 50 efavirenz EFV 50 FOLOTYN ® 50 Randomized Placebo Controlled 50 blinded randomized controlled 50 FOLFOX 50 Acute Coronary Syndromes ACS 50 CARE HF 50 Safinamide 50 darunavir ritonavir 50 NICE SUGAR 50 Phase III Clinical Trials 50 Dose Ranging Study 50 EchoCRT 50 pain palliation 50 8mg/kg 50 PEG INTRON R 50 Pivotal Phase III 50 Phase III VISTA 50 #mg BID [003] 50 mGluR5 NAM 50 weekly subcutaneous injections 50 VIRAMUNE XR 50 Phase III ALLEGRO 50 efficacy endpoints 50 candesartan cilexetil 50 mg TID 50 XIENCE V demonstrated 50 subcutaneous methylnaltrexone 50 specific CCR9 antagonist 50 blind randomized multicenter 50 Combination REOLYSIN R 50 Testosterone MDTS ® 50 MEND CABG II 50 low dose cytarabine 50 Pivotal Study 50 relapsing remitting multiple sclerosis 50 relapsed myeloma 50 Phase III ThermoDox 50 dosage regimens 50 ThermoDox R 50 Clinical Trial 50 PEGINTRON TM 50 dirucotide MBP# 50 NEVO RES 50 MoxDuo 50 Degarelix 50 oral diclofenac 50 EDEMA4 50 headache nasopharyngitis 50 beta2 agonist 50 oral sapacitabine 50 relapsed MM 50 acyclovir Lauriad R 50 prospective observational cohort 50 designated HVTN 50 telaprevir dosed 50 plus prednisone 50 VITAL Trial 50 Phase 50 NOXAFIL 50 MAGE A3 ASCI 50 dextromethorphan quinidine 50 Double Blind Placebo 50 Rosuvastatin 50 TAXUS V 50 efficacy tolerability 50 pomalidomide 50 DAPT Study 50 GAMMAGARD 50 PSN# [002] 50 PRIMO CABG 50 melphalan prednisone 50 subgroup analyzes 50 somatostatin analog 50 Microplasmin 50 IIa clinical trial 50 bupropion SR 50 PREVAIL 50 coadministration 50 PERSEUS 50 Navelbine 50 irbesartan 50 Phase 2a Study 50 LIALDA 50 DPNP 50 EmbraceAC 50 antiviral activity 50 immunogenicity 50 Phase #b/#a trial 50 ROZEREM TM 50 European Sepsis Trial 50 mg doses 49 NATRECOR R 49 thorough QT 49 LUMINATE 49 patients undergoing percutaneous 49 composite endpoint 49 mcg QD 49 Cholesterol Levels SPARCL 49 #mg BID [001] 49 BARI 2D 49 Oral NKTR 49 AZX# 49 Prostate AdenoCarcinoma Treatment 49 Thrombolysis 49 oral formulation 49 ARIXTRA 49 q8h 49 ILLUMINATE 49 solithromycin 49 IIa clinical 49 peripherally acting 49 mcg dose 49 ZYBRESTAT 49 RG# [001] 49 brivaracetam 49 angiotensin analog 49 Androxal TM 49 sorafenib Nexavar 49 sNDA submission 49 CAPACITY trials 49 mcg BID 49 MGd 49 HORIZONS AMI trial 49 virus HCV protease inhibitor 49 3TC lamivudine Epivir 49 cetrorelix 49 evaluable subjects 49 #mg/m# [002] 49 Long Term Efficacy 49 EXPLORE Xa 49 ENGAGE AF TIMI 49 Efficacy Results 49 unique alkylating agent 49 EOquin TM 49 metastatic hormone refractory 49 Adalimumab 49 GATTEX ™ 49 tesmilifene 49 HGS ETR1 49 TMC# [001] 49 teduglutide 49 Blind Placebo Controlled Trial 49 direct thrombin inhibitor 49 oral ibandronate 49 Naive Patients 49 mixed dyslipidemia 49 relapsed refractory multiple myeloma 49 bevirimat Study 49 mcg 49 venlafaxine XR 49 adalimumab 49 SYMMETRY trial 49 CYPHER R stent 49 DASISION 49 pharmacodynamic effects 49 goserelin 49 investigational drug 49 hyperphenylalaninemia HPA due 49 evaluating carfilzomib 49 recurrent GBM 49 Dapagliflozin 49 telmisartan 49 pharmacokinetic PK profile 49 AVADO 49 JANUVIA 49 ISENTRESS 49 HCV infected 49 IMPACT IMmunotherapy 49 mg d 49 Phase IIb IIIa 49 Ozarelix 49 glufosfamide 49 Afatinib 49 lopinavir r 49 trials BLISS 49 Proellex TM 49 PROPEL 49 PARTNER Trial 49 PD LID 49 Health Initiative WHI 49 boosted protease inhibitor 49 vinorelbine 49 Elagolix 49 cell lymphoma CTCL 49 pharmacodynamic profiles 49 prospective multicenter study 49 CURRENT OASIS 7 49 risperidone Risperdal 49 EXPAREL TM 49 Primary endpoints 49 Systemic Sclerosis 49 varespladib 49 plus dexamethasone 49 Tiotropium 49 Phase #b/#a clinical 49 Sibutramine Cardiovascular Outcomes 49 SUTENT ® 49 Pegasys plus Copegus 49 severe oral mucositis 49 Screening Trial 49 oral Janus kinase 49 trabedersen 49 Double Blind Randomized 49 Val MARC 49 PHX# 49 intravenous dose 49 GEM OS1 49 sirolimus eluting 49 Ophena TM 49 KAPIDEX 49 Phase 2b dose 49 Ranolazine 49 Sym# 49 visilizumab 49 prucalopride 49 miconazole Lauriad ® 49 Valsartan 49 COPEGUS ribavirin 49 Teriflunomide 49 refractory CLL 49 Multicenter Phase 49 RESOLUTE 49 R# #mg BID 49 Pegasys ® 49 dose pharmacokinetic 49 QLT# 49 RLAI 49 RADIANT 49 eculizumab 49 Placebo Controlled Trial 49 afatinib 49 longitudinal observational study 49 Feasibility Trial 49 docetaxel Taxotere ® 49 eosinophilic asthma 49 galiximab 49 celgosivir 49 cathepsin K inhibitor 49 MVA MUC1 IL2 49 CIMZIA R 49 PRX # 49 ferric citrate 49 opioid naive 49 albinterferon alfa 2b 49 Peg IFN 49 Demonstrates Positive 49 Completes Enrollment 49 Randomized Study 49 registrational Phase 49 Diabetic Macular Edema 49 DP b# 49 HeFT 49 lopinavir ritonavir 49 edoxaban 49 tenofovir emtricitabine 49 NP2 Enkephalin 49 NSABP C 49 Tracleer R 49 unfractionated heparin UFH 49 Aggressive Reduction 49 ALVESCO 49 Left Ventricular Dysfunction 49 CYPHER ® Sirolimus eluting 49 intermittent dosing 49 prespecified 49 Betaferon R 49 ARCOXIA 49 Ovarian PLCO Cancer 49 plus COPEGUS 49 metreleptin 49 liposome injection 49 neratinib 49 DermaVir Patch 49 PREZISTA ritonavir 49 daily Infergen 49 Phase III ADT 49 Novel Oral 49 NGX# 49 eszopiclone 49 Maximum Tolerated Dose 49 Platelet Inhibition 49 subcutaneous formulation 49 carboplatin 49 Board DSMB 49 MSI #F 49 Observational Study 49 Stenting Trial CREST 49 μg kg 49 Phase 2a proof 49 KB# [002] 49 R#/MEM # 48 lorcaserin Phase 48 placebo PBO 48 dose limiting toxicities 48 relapsed APL 48 cluster randomized controlled 48 intravitreal injection 48 Zerenex 48 secondary efficacy endpoint 48 Clolar ® 48 albiglutide 48 rt PA 48 perampanel 48 #mg QD [001] 48 plus gemcitabine 48 REBETOL 48 Randomized Double Blind 48 sunitinib 48 Anturol TM 48 DDP# 48 pertuzumab 48 ofatumumab 48 liver transplant recipients 48 estramustine 48 IFN alfa 48 oxycodone CR 48 dosing schedules 48 stage IIIB 48 dexamethasone Decadron 48 Clinical Trial Evaluating 48 hyperlipidemic 48 inhibitor RG# 48 Randomized Controlled Trial 48 DLTs 48 EMPHASIS HF trial 48 Zenvia Phase III 48 timepoint 48 Nasdaq PGNX today 48 etanercept 48 FOLFOX6 chemotherapy regimen 48 randomization 48 Sapacitabine 48 ATACAND 48 demonstrated clinically meaningful 48 aripiprazole Abilify 48 pharmacokinetics pharmacodynamics 48 Protelos 48 Phase IIb clinical trials 48 ID NCT# 48 normotensive 48 PROMACTA 48 budesonide foam 48 unresectable HCC 48 TMC# r 48 ribavirin Copegus 48 EVIZON 48 pimecrolimus cream 48 intravenous dosing 48 velafermin 48 HYVET 48 pharmacokinetic profiles 48 Dose escalation 48 antiretroviral naïve 48 salmeterol fluticasone 48 COPEGUS 48 liposomal formulation 48 doxorubicin docetaxel 48 CRLX# 48 Xeloda ® 48 HCV genotype 1 48 Intervention Trial 48 Diabetic Macular Edema DME 48 SYNTAX trial 48 tapentadol ER 48 allosteric modulator NAM 48 AVERROES 48 carboplatin paclitaxel 48 Clinical Outcomes Utilizing Revascularization 48 Monitoring ABPM 48 TYGACIL 48 retinal vein occlusion induced 48 Cloretazine 48 polymerase inhibitor 48 SEROQUEL 48 eprotirome 48 MoxDuo TM IR 48 satraplatin Phase 48 generation PNP inhibitor 48 mg/m2 48 elotuzumab 48 cisplatin gemcitabine 48 elagolix 48 Augment Injectable 48 #mg dose [003] 48 VA# [002] 48 Pharmacokinetics PK 48 CHOP chemotherapy 48 pegylated interferon alpha 48 NVA# 48 RezularTM 48 q#h 48 rhIGF-I/rhIGFBP-3 48 unstable angina UA 48 XL# SAR# 48 NEVO 48 Lodotra TM 48 ACAM FLU 48 atorvastatin Lipitor 48 LPV r 48 interferon beta 1b 48 bendamustine 48 vidofludimus 48 Eluting Stent 48 ENDEAVOR III 48 fistulizing Crohn disease 48 Ixempra 48 BiTE R 48 worsening thrombocytopenia 48 Subgroup Analysis 48 COU AA 48 SIMPADICO 48 Taxotere R 48 Capesaris 48 eptifibatide 48 mg/m2 cohort 48 IMC A# 48 TEMSO 48 serotonin norepinephrine reuptake inhibitor 48 deferiprone 48 oral FTY# 48 PROMUS Element Stent 48 iPrEx 48 bicifadine